Search

Displaying results 1681 - 1690 of 4004 in total
  1. Drug

    Cediranib

    go.drugbank.com/drugs/DB04849
    Investigational

    The novel indole-ether quinazoline Cediranib is a highly potent (IC50 < 1 nmol/L) ATP-competitive inhibitor of recombinant KDR tyrosine kinase in vitro. It is being developed clinically as a once-daily oral therapy for the treatment o...

  2. Drug

    Antroquinonol

    go.drugbank.com/drugs/DB12326
    Investigational

    Antroquinonol has been used in trials studying the treatment of Hyperlipidemias, Non-small Cell Lung Cancer, and Non-small Cell Lung Cancer Stage IV.

  3. Target

    Probable ATP-dependent RNA helicase DDX5

    go.drugbank.com/bio_entities/BE0009162
    TargetHumans

    Involved in the alternative regulation of pre-mRNA splicing; its RNA helicase activity is necessary for increasing tau exon 10 inclusion and occurs in a RBM4-dependent manner. Binds to the tau pre-mRNA in the stem-loop region downstream ...

    Synonyms: DEAD box protein 5
  4. Indication

    Premature Births

    go.drugbank.com/conditions/DBCOND0043809
    Drugs: Atosiban · Hydroxyprogesterone caproate · Ritodrine
    Synonyms: Baby born premature
  5. Drug

    Bulevirtide

    go.drugbank.com/drugs/DB15248
    ApprovedInvestigational

    It was first approved for use in the EU on May 28, 2020; bulevirtide has been granted PRIME scheme eligibility and Orphan Drug Designation by the European Medicines Agency.

  6. Drug

    Atazanavir

    go.drugbank.com/drugs/DB01072
    ApprovedInvestigational

    Food and Drug Administration (FDA) approved atazanavir on June 20, 2003. … Atazanavir is distinguished from other PIs in that it can be given once daily (rather than requiring multiple doses per day) and has lesser effects on the patient's lipid profile (the amounts of cholesterol

  7. Drug

    Betahistine

    go.drugbank.com/drugs/DB06698
    ApprovedInvestigational

    It is thought to reduce symptoms through its actions on histamine receptors. … It has a significant impact on both the physical and social functioning of affected individuals.

  8. Drug

    Lactulose

    go.drugbank.com/drugs/DB00581
    ApprovedInvestigational

    [L6202] Nevertheless, although lactulose received formal FDA approval in 1977 and has since become a readily available generic and brand-name non-prescription medication listed on the World Health

  9. Drug

    Imlifidase

    go.drugbank.com/drugs/DB15258
    ApprovedInvestigational

    [A225836] As a result, highly sensitized individuals experience marked delays on transplant lists due to the challenges associated with procuring an HLA compatible donor graft. … A225916] Patients who have developed human leukocyte antigen (HLA) sensitization from prior exposure to blood products, pregnancy, or any other circumstance which may have resulted in exposure to non-self

  10. Drug

    Ubrogepant

    go.drugbank.com/drugs/DB15328
    ApprovedInvestigational

    [A189207] Ubrogepant was approved by Health Canada on November 10, 2022. … [L10926] It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine.